NanJing Pharmaceutical Co Ltd
SSE:600713
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
NanJing Pharmaceutical Co Ltd
NanJing Pharmaceutical Co Ltd
Cash & Cash Equivalents
NanJing Pharmaceutical Co Ltd
Cash & Cash Equivalents Peer Comparison
1099
601607
600998
000963
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
NanJing Pharmaceutical Co Ltd
SSE:600713
|
Cash & Cash Equivalents
¥2.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
5%
|
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Cash & Cash Equivalents
¥34.4B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
9%
|
|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Cash & Cash Equivalents
¥27.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Cash & Cash Equivalents
¥8.8B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
16%
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Cash & Cash Equivalents
¥10.9B
|
CAGR 3-Years
28%
|
CAGR 5-Years
23%
|
CAGR 10-Years
29%
|
|
|
Huadong Medicine Co Ltd
SZSE:000963
|
Cash & Cash Equivalents
¥4.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
18%
|
CAGR 10-Years
16%
|
See Also
What is NanJing Pharmaceutical Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
2.2B
CNY
Based on the financial report for Mar 31, 2024, NanJing Pharmaceutical Co Ltd's Cash & Cash Equivalents amounts to 2.2B CNY.
What is NanJing Pharmaceutical Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
5%
Over the last year, the Cash & Cash Equivalents growth was 58%. The average annual Cash & Cash Equivalents growth rates for NanJing Pharmaceutical Co Ltd have been 7% over the past three years , -3% over the past five years , and 5% over the past ten years .
You don't have any saved screeners yet
